How beta and gamma synuclein affect alpha-synuclein at brain synapses

The Impact of Beta- and Gamma-Synucleins on Alpha-Synuclein's Synaptic Function

NIH-funded research Weill Medical Coll of Cornell Univ · NIH-11334311

This research looks at whether two related proteins, beta- and gamma-synuclein, change how alpha-synuclein helps brain cells communicate in conditions like Parkinson’s disease and Lewy body dementia.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionWeill Medical Coll of Cornell Univ NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-11334311 on NIH RePORTER

What this research studies

From a patient perspective, scientists will study how three synuclein proteins work together at nerve endings that release brain chemicals. They will use mice engineered to lack beta or gamma synuclein, lab-grown cells, and purified proteins to watch how these proteins influence vesicle clustering and the machinery (SNARE complexes) that lets nerve cells send signals. The team will also measure how those changes affect vesicle recycling and overall neuronal activity. The work focuses on basic brain biology that could explain why synuclein proteins go wrong in diseases such as Parkinson’s and Lewy body dementia.

Who could benefit from this research

Good fit: People with Parkinson’s disease, Lewy body dementia, or other synuclein-related dementias who want to follow research progress or consider future participation in related studies would be most connected to this work.

Not a fit: Patients whose dementia is caused by non-synuclein processes may not see direct benefit from these findings in the near term.

Why it matters

Potential benefit: If successful, this work could identify new targets to prevent or slow synuclein-related diseases like Parkinson’s and Lewy body dementia.

How similar studies have performed: Alpha-synuclein’s role in disease is well established, but studying the normal roles of beta- and gamma-synuclein and their interaction with alpha-synuclein is relatively new and not yet proven in humans.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer's Disease and its related dementiasAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease and related forms of dementiaAlzheimer's disease or a related dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.